Is Merck Stock About To Crash?

The article argues that while Merck's higher revenue growth and cash flow margins, driven by Keytruda, make it seemingly more attractive than Johnson & Johnson, investors should consider the risk of Keytruda's U.S. market exclusivity expiring in 2028. The expected decline in Keytruda sales, potentially mirroring the sharp drops seen with Humira and Herceptin post-patent expiration, poses a significant threat to Merck's valuation, highlighting the importance of diversification and balancing risk-reward in investment decisions, potentially favoring a more stable stock like J&J despite its lower growth.

Analysis

Johnson & Johnson (JNJ), trading at approximately 17 times trailing earnings, presents a different investment profile compared to Merck (MRK), which trades at around 13 times. While Merck exhibits stronger recent financial performance, with nearly 10% average revenue growth versus J&J’s 4% and superior operating cash flow margins of 33% compared to J&J’s 28%, this outperformance is heavily reliant on its oncology drug, Keytruda. Keytruda accounted for nearly half of Merck's revenue, reaching $29 billion in sales last year, and is projected to peak around $36 billion by 2028. However, a significant risk looms as Keytruda is set to lose U.S. market exclusivity in 2028. Historical precedents, such as AbbVie’s Humira, which saw sales plummet nearly 60% within two years post-patent expiration, and Roche’s Herceptin, suggest a potentially sharp decline for Keytruda sales, possibly to under $20 billion or even $15 billion, once biosimilar competition emerges. This impending patent cliff poses a considerable threat to Merck's future growth trajectory and valuation, highlighting a substantial concentration risk. In contrast, J&J, with over a century of operations, is positioned as a more stable, albeit slower-growing, entity. The comparison underscores a critical risk-reward trade-off, where Merck's current attractive metrics are counterbalanced by a significant future revenue vulnerability. The general sentiment surrounding Merck is strongly negative, with a sentiment score of -0.8 for MRK specifically, reflecting these concerns.

Key Decisions for Investors

• Investors holding or considering Merck (MRK) should critically evaluate the significant concentration risk associated with Keytruda and the impending patent cliff in 2028, which is likely to materially impact future revenue and valuation.
• Consider Johnson & Johnson (JNJ) as a potentially more stable, albeit lower-growth, alternative within the pharmaceutical sector, particularly if risk aversion or portfolio diversification away from single-drug dependencies is a priority.
• Portfolio managers should weigh the near-term growth and margin advantages of Merck against the long-term sustainability challenges, and monitor developments related to Keytruda's biosimilar competition closely.
• Assess the relative attractiveness of these pharmaceutical stocks against broader market ETFs or cash, factoring in the specific risk-return profile each investment offers in light of Keytruda's future.